TY - THES A1 - Stürmer, Andrea T1 - Interaktionen und Lokalisationen der Replikationsproteine der Maus T1 - Interactions and Localizations of murine Replication Proteins N2 - Die Initiation der DNA-Replikation in Eukaryonten ist ein hochkonservierter Prozess, der in drei Stufen unterteilt werden kann. Im ersten Schritt bindet der „origin recognition complex“ (ORC) an Replikationsorigins innerhalb chromosomaler DNA, wodurch eine Assemblierung des präreplikativen Komplexes an diesen Startpunkten ausgelöst wird. An den ORC lagern sich anschließend die Proteine CDC6 und RLF-B/CDT1 an, die beide schließlich für die Rekrutierung des heterohexameren MCM-Komplexes verantwortlich sind. Durch die Aktivität der Kinase CDC7/DBF4 wird der Origin für den Start der DNA-Replikation lizenziert, sobald die finale Anlagerung des Initiationsfaktors CDC45 den präreplikativen Komplex vervollständigt hat. Ein Ziel der vorliegenden Arbeit war es, das komplexe Netzwerk von Protein-Protein-Interaktionen zwischen den verschiedenen Initiationsfaktoren durch FRET-Studien aufzuklären. Es konnten Interaktionen zwischen MCM5 und MCM3, MCM5 und MCM7, ORC5 und MCM7, sowie CDT1 und MCM6 in vivo nachgewiesen werden. Die vorliegende Arbeit hatte weiterhin die Untersuchung der intrazellulären Lokalisation der sechs murinen MCM-Proteine in Fibroblasten-Zellen der Maus zum Ziel.Lokalisationsstudien der EGFP-gekoppelten MCM-Proteine zeigten, dass die Proteine EGFP-MCM4, MCM4-EGFP, MCM4-NLS-EGFP, EGFP-MCM5, MCM5-EGFP, MCM5-NLS-EGFP, und EGFP-MCM7 u.a. am Centrosom lokalisiert sind. Durch Immunfluoreszenz-Färbung mit Antikörpern gegen eine konservierte Domäne aller sechs MCM-Untereinheiten sowie mit spezifischen MCM3- und MCM6-Antikörpern konnte eine centrosomale Lokalisation auch für die endogenen Proteine nachgewiesen werden. Zusätzlich zu den Lokalisationsanalysen konnte über Immunpräzipitationsstudien gezeigt werden, dass MCM3 und MCM6 mit dem centrosomalen Protein g-Tubulin präzipitierbar sind. Die Tatsache, dass alle Untereinheiten des MCM-Komplexes mit dem Centrosom assoziiert sind, deutet darauf hin, dass die MCM-Proteine am Centrosom als Multiproteinkomplex gebunden sind. Da MCM3 und MCM6 auch in allen Mitose-Stadien an das Centrosom gebunden sind, kann von einer funktionellen Aufgabe dieser Proteine während der Zellteilung ausgegangen werden. Im letzten Teil dieser Arbeit sollte die Funktion der MCM-Proteine am Centrosom durch „knock-down“ des Proteins MCM3 mittels RNA-Interferenz-Studien untersucht werden. Ziel war, ein induzierbares MCM3-siRNA-exprimierendes System zu etablieren. Das gezielte An- und Abschalten der MCM3siRNA-Transkription sollte durch das TetOn-System ermöglicht werden. Bei diesem System wird durch Zugabe von Doxycyclin die Transkription aktiviert, bei Abwesenheit von Doxycyclin wird sie abgeschaltet. Auf dieser Basis wurde der Einfluss von Doxycyclin auf das Wachstumsverhalten der MCM3siRNA-exprimierenden Zelllinie untersucht. Im Vergleich zu NIH/3T3-Zellen und NIH/3T3-TetOn-Zellen konnte eine deutlich reduzierte Proliferation bei Behandlung der Zellen mit Doxycyclin beobachtet werden. Diese Ergebnisse deuten auf eine durch Produktion von MCM3siRNA verursachte Störung des Zellwachstums hin. Zusätzlich beeinflusst die durch Doxycyclin induzierte Synthese von MCM3siRNA die Zellzyklusverteilung. So befinden sich nach Doxycyclinbehandlung mehr Zellen in der G2/M-Phase als in unbehandelten, asynchronen NIH/3T3-Zellen. Die MCM3-Proteinmenge wurde nach 19 Tagen Doxycyclinbehandlung fast vollständig durch die produzierte MCM3siRNA herunterreguliert. Um einen möglichen Einfluss der MCM3siRNA auf andere MCM-Proteine zu untersuchen, wurde der Protein-Level von MCM6 analysiert. Dabei wurde eine vermehrte MCM6-Expression nachgewiesen. Diese Beobachtung deutet darauf hin, dass durch Bildung von MCM3siRNA der Expressions-Level von MCM6 beeinflusst wird. Auffällig häufig lagen in MCM3-„knock-down“-Zellen mehrere Zellkerne vor. Neben Zellen mit zwei Zellkernen finden sich auch Zellen mit einer ungeraden Anzahl an Zellkernen. Demnach durchlaufen die Zellkerne in einer Zelle unterschiedliche Zellzyklusstadien. Die Phänotypen, die nach Transkription der MCM3siRNA beobachtet wurden, sind komplex und zeigen Defekte in zahlreichen Mitose-Stadien. Das Auftreten multinukleärer Zellen ist auf eine fehlende Cytokinese zurückzuführen. Die Mikrotubuli waren in den MCM3-„knock-down“-Zellen nur unzureichend organisiert, wobei sie kaum mit der Zellperipherie verankert waren. Diese Resultate weisen darauf hin, dass die MCM-Proteine neben ihrer essentiellen Rolle in der Ausbildung des präreplikativen Komplexes eine zusätzliche Funktion in der Mitose ausüben. N2 - The initiation of DNA replication is a highly conserved process which is subdivided into three steps. The first step is the binding of the “origin recognition complex” (ORC) to the replication origins in chromosomal DNA which triggers the assembly of the prereplicative complex at the origins. Subsequently the proteins CDC6 and the RLF-B/CDT1 bind to ORC which are both responsible for the recruitment of the heterohexameric MCM-complex to the prereplicative complex (preRC). The kinase CDC7/DBF4 licenses the origin after completion of the preRC by binding of the CDC45 protein. One task of this work was to dissolve the complex network of protein-protein interactions between the different initiator proteins using the method of FRET (Fluorescence Resonance Energy Transfer). Interactions were found between MCM5 and MCM3, MCM5 and MCM7, ORC5 and MCM7 as well as between CDT1 and MCM6. A further task of this work was to study the intracellular localization of the six murine MCM proteins in murine fibroblasts.In a MCM2-EGFP expressing cell population multinucleated cells occurred frequently. This indicates an incorrect cell division caused by overexpression of MCM2-EGFP and to a possible role of MCM2 in mitosis. Inspecting the intracellular localization of EGFP-fused MCM-proteins was shown, that EGFP-MCM4, MCM4-EGFP, MCM4-NLS-EGFP, EGFP-MCM5, MCM5-EGFP, MCM5-NLS-EGFP, and EGFP-MCM7 were localized in the centrosomes. In contrast, the proteins MCM2-EGFP, EGFP-MCM2, MCM3-EGFP, EGFP-MCM3, MCM6-EGFP, MCM6-NLS-EGFP, MCM7-EGFP and MCM7-NLS-EGFP are not associated with centrosomes. The localization of endogeneous MCM proteins was analyzed by immunostaining using antibodies against a conserved region among all MCM proteins and also with specific antibodies against MCM3 and MCM6. Centrosomal localization was observed for the MCM proteins and in particular for MCM3 and MCM6. In addition to localization studies, immunoprecipitations showed that MCM3 and MCM6 precipitate with the centrosomal protein g-tubulin. The fact that all MCM proteins assemble at the centrosome, indicates that the MCM proteins act as a multiprotein complex at the centrosome. Since MCM3 and MCM6 are bound to centrosomes in all stages of mitosis these proteins may play a role in the progression of cell division. In the last part of this work, the function of MCM3 at the centrosome was analyzed by protein knock-down using the method of RNA interference. To approach this, an inducible MCM3siRNA-expressing system was established. Switching the transcription of MCM3siRNA on and off was made feasible using the TetOn-System. In this system the transcription is activated by addition of doxycycline, without doxycycline the transcription is switched-off. The influence of doxycycline on cell growth of the MCM3siRNA-expressing cell line was analyzed. By comparison to NIH/3T3 cells and NIH/3T3-TetOn cells a significantly reduced proliferation rate was observed after treatment with doxycycline. These results suggest a disturbance of cell growth by MCM3siRNA production. After treatment with doxycycline more cells are accumulated in G2/M phase compared to untreated cells. The expression of MCM3 was almost completely knocked-down by treatment of cells with doxycycline for 19 days. To analyze the influence of MCM3siRNA on other MCM proteins, the protein level of MCM6 was examined. An increased MCM6 expression was observed. This implies that MCM3siRNA influences the expression level of MCM6. More nuclei were frequently observed in MCM3 knocked-down cells. Cells with two nuclei as well as cells with an impaired number of nuclei were observed, indicating that probably the nuclei pass thruogh different cell cycle stages. Phenotypes observed after expression of MCM3siRNA showed defects in multiple stages of mitosis. The presence of multinucleated cells is apparently due to a blocked cytokinesis. Microtubuli were insufficiently organized and were deficiently bound to the cellular periphery. These results indicate an essential role of the MCM proteins in mitosis besides its described role in the establishment of the prereplicative complex. KW - Replikation KW - Maus KW - Proteine KW - Interaktion KW - Replikation KW - Lokalisation KW - Interaktion KW - Proteine KW - replication KW - localization KW - interaction KW - proteins Y1 - 2004 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-9563 ER - TY - THES A1 - Syagaylo, Yana T1 - Strukturelle und funktionelle Untersuchung der Promotorregionen der menschlichen PAX3-, PAX6- und PAX7-Gene: Bedeutung von Polymorphismen für schizophrene Erkrankungen T1 - Structural and functional characterization of the promoter regions of the human PAX3, PAX6 and PAX7 genes: relevance of polymorphisms for schizophrenia N2 - Das Ziel dieser Arbeit war die Klärung der phänotypischen Konsequenzen struktureller Variationen in den regulatorischen Regionen einiger für psychische Erkrankungen potentiell relevanter Entwicklungsgene. Die Pax-Gene sind Mitglieder einer Familie der Transkriptionsfaktoren, die sowohl mehrere Schritte in der Embryogenese als auch Aufrechterhaltung des Differenzierungszustandes der Zellen einiger adulten Gewebe kontrollieren. Im Rahmen dieser Fragestellung wurden die Promotorregionen der menschlichen PAX3-, PAX6- und PAX7-Gene charakterisiert. Weiterhin wurden funktionelle Folgen der mit diesen Promotoren assoziierten Repeat-Polymorphismen auf die Expression dieser Gene untersucht. Schliesslich wurde die Relevanz für die psychischen Erkrankungen wie die Schizophrenie getestet. N2 - The aim of this study was the elucidation of phenotypical consequences of structural variations in regulatory regions of developmental genes that are potentially relevant for mental disease. The Pax genes are members of a family of evolutionary conserved transcription factors, which control several steps in the embryogenesis as well as maintain the differentiation status of cells in adult tissues. In this context the promoter regions of the human PAX3, PAX6 and PAX7 genes were characterized. Therefore, functional effects of the polymorphic repetitive elements in the gene promoter regions on the expression of these genes were examined. Finally, the relevance for the psychiatric diseases like schizophrenia was tested. KW - Schizophrenie KW - Transkriptionsfaktor KW - Genanalyse KW - Promotor KW - PAX-Gene KW - Promotor KW - Promotorpolymorphismus KW - Schizophrenieerkrankung KW - PAX genes KW - promoter KW - promoter polymorphism KW - schizophrenia Y1 - 2002 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-5459 ER - TY - JOUR A1 - Szalay, Aladar A A1 - Weibel, Stephanie A1 - Hofmann, Elisabeth A1 - Basse-Luesebrink, Thomas Christian A1 - Donat, Ulrike A1 - Seubert, Carolin A1 - Adelfinger, Marion A1 - Gnamlin, Prisca A1 - Kober, Christina A1 - Frentzen, Alexa A1 - Gentschev, Ivaylo A1 - Jakob, Peter Michael T1 - Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer JF - Journal of Translational Medicine N2 - Background Malignant pleural effusion (MPE) is associated with advanced stages of lung cancer and is mainly dependent on invasion of the pleura and expression of vascular endothelial growth factor (VEGF) by cancer cells. As MPE indicates an incurable disease with limited palliative treatment options and poor outcome, there is an urgent need for new and efficient treatment options. Methods In this study, we used subcutaneously generated PC14PE6 lung adenocarcinoma xenografts in athymic mice that developed subcutaneous malignant effusions (ME) which mimic pleural effusions of the orthotopic model. Using this approach monitoring of therapeutic intervention was facilitated by direct observation of subcutaneous ME formation without the need of sacrificing mice or special imaging equipment as in case of MPE. Further, we tested oncolytic virotherapy using Vaccinia virus as a novel treatment modality against ME in this subcutaneous PC14PE6 xenograft model of advanced lung adenocarcinoma. Results We demonstrated significant therapeutic efficacy of Vaccinia virus treatment of both advanced lung adenocarcinoma and tumor-associated ME. We attribute the efficacy to the virus-mediated reduction of tumor cell-derived VEGF levels in tumors, decreased invasion of tumor cells into the peritumoral tissue, and to viral infection of the blood vessel-invading tumor cells. Moreover, we showed that the use of oncolytic Vaccinia virus encoding for a single-chain antibody (scAb) against VEGF (GLAF-1) significantly enhanced mono-therapy of oncolytic treatment. Conclusions Here, we demonstrate for the first time that oncolytic virotherapy using tumor-specific Vaccinia virus represents a novel and promising treatment modality for therapy of ME associated with advanced lung cancer. KW - Oncolytic virotherapy KW - Malignant effusion KW - Lung cancer KW - VEGF KW - Lungenkrebs KW - Vascular endothelial Growth Factor Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-96016 UR - http://www.translational-medicine.com/content/11/1/106 ER - TY - JOUR A1 - Tolay, Nazife A1 - Buchberger, Alexander T1 - Role of the ubiquitin system in stress granule metabolism JF - International Journal of Molecular Sciences N2 - Eukaryotic cells react to various stress conditions with the rapid formation of membrane-less organelles called stress granules (SGs). SGs form by multivalent interactions between RNAs and RNA-binding proteins and are believed to protect stalled translation initiation complexes from stress-induced degradation. SGs contain hundreds of different mRNAs and proteins, and their assembly and disassembly are tightly controlled by post-translational modifications. The ubiquitin system, which mediates the covalent modification of target proteins with the small protein ubiquitin (‘ubiquitylation’), has been implicated in different aspects of SG metabolism, but specific functions in SG turnover have only recently emerged. Here, we summarize the evidence for the presence of ubiquitylated proteins at SGs, review the functions of different components of the ubiquitin system in SG formation and clearance, and discuss the link between perturbed SG clearance and the pathogenesis of neurodegenerative disorders. We conclude that the ubiquitin system plays an important, medically relevant role in SG biology. KW - 26S proteasome KW - p97/VCP KW - Cdc48 KW - DUB KW - G3BP KW - granulostasis KW - granulophagy KW - ALS Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-284061 SN - 1422-0067 VL - 23 IS - 7 ER - TY - JOUR A1 - Tolay, Nazife A1 - Buchberger, Alexander T1 - Comparative profiling of stress granule clearance reveals differential contributions of the ubiquitin system JF - Life Science Alliance N2 - Stress granules (SGs) are cytoplasmic condensates containing untranslated mRNP complexes. They are induced by various proteotoxic conditions such as heat, oxidative, and osmotic stress. SGs are believed to protect mRNPs from degradation and to enable cells to rapidly resume translation when stress conditions subside. SG dynamics are controlled by various posttranslationalmodifications, but the role of the ubiquitin system has remained controversial. Here, we present a comparative analysis addressing the involvement of the ubiquitin system in SG clearance. Using high-resolution immuno-fluorescence microscopy, we found that ubiquitin associated to varying extent with SGs induced by heat, arsenite, H2O2, sorbitol, or combined puromycin and Hsp70 inhibitor treatment. SG-associated ubiquitin species included K48- and K63-linked conjugates, whereas free ubiquitin was not significantly enriched. Inhibition of the ubiquitin activating enzyme, deubiquitylating enzymes, the 26S proteasome and p97/VCP impaired the clearance of arsenite- and heat-induced SGs, whereas SGs induced by other stress conditions were little affected. Our data underline the differential involvement of the ubiquitin system in SG clearance, a process important to prevent the formation of disease-linked aberrant SGs. KW - phase transition KW - quality control KW - protein KW - inhibition KW - complexity KW - separation KW - diversity KW - autophagy KW - ALS KW - P97 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259810 VL - 4 IS - 5 ER - TY - JOUR A1 - Tomei, Sara A1 - Adams, Sharon A1 - Uccellini, Lorenzo A1 - Bedognetti, Davide A1 - De Giorgi, Valeria A1 - Erdenebileg, Narnygerel A1 - Libera Ascierto, Maria A1 - Reinboth, Jennifer A1 - Liu, Qiuzhen A1 - Bevilacqua, Generoso A1 - Wang, Ena A1 - Mazzanti, Chiara A1 - Marincola, Francesco M. T1 - Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population JF - Medical Oncology N2 - HRAS belongs to the RAS genes superfamily. RAS genes are important players in several human tumors and the single-nucleotide polymorphism rs12628 has been shown to contribute to the risk of bladder, colon, gastrointestinal, oral, and thyroid carcinoma. We hypothesized that this SNP may affect the risk of cutaneous melanoma as well. HRAS gene contains a polymorphic region (rs112587690), a repeated hexanucleotide -GGGCCT- located in intron 1. Three alleles of this region, P1, P2, and P3, have been identified that contain two, three, and four repeats of the hexanucleotide, respectively. We investigated the clinical impact of these polymorphisms in a case–control study. A total of 141 melanoma patients and 118 healthy donors from the North America Caucasian population were screened for rs12628 and rs112587690 polymorphisms. Genotypes were assessed by capillary sequencing or fragment analysis, respectively, and rs12628 CC and rs112587690 P1P1 genotypes significantly associated with increased melanoma risk (OR = 3.83, p = 0.003; OR = 11.3, p = 0.033, respectively), while rs112587690 P1P3 frequency resulted significantly higher in the control group (OR = 0.5, p = 0.017). These results suggest that rs12628 C homozygosis may be considered a potential risk factor for melanoma development in the North American population possibly through the linkage to rs112587690. KW - HRAS KW - polymorphism KW - melanoma KW - rs12628 KW - rs112587690 Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-126834 VL - 29 IS - 5 ER - TY - JOUR A1 - Tsoneva, Desislava A1 - Minev, Boris A1 - Frentzen, Alexa A1 - Zhang, Qian A1 - Wege, Anja K. A1 - Szalay, Aladar A. T1 - Humanized Mice with Subcutaneous Human Solid Tumors for Immune Response Analysis of Vaccinia Virus-Mediated Oncolysis JF - Molecular Therapy Oncolytics N2 - Oncolytic vaccinia virus (VACV) therapy is an alternative cancer treatment modality that mediates targeted tumor destruction through a tumor-selective replication and an induction of anti-tumor immunity. We developed a humanized tumor mouse model with subcutaneous human tumors to analyze the interactions of VACV with the developing tumors and human immune system. A successful systemic reconstitution with human immune cells including functional T cells as well as development of tumors infiltrated with human T and natural killer (NK) cells was observed. We also demonstrated successful in vivo colonization of such tumors with systemically administered VACVs. Further, a new recombinant GLV-1h376 VACV encoding for a secreted human CTLA4-blocking single-chain antibody (CTLA4 scAb) was tested. Surprisingly, although proving CTLA4 scAb’s in vitro binding ability and functionality in cell culture, beside the significant increase of CD56\(^{bright}\) NK cell subset, GLV-1h376 was not able to increase cytotoxic T or overall NK cell levels at the tumor site. Importantly, the virus-encoded β-glucuronidase as a measure of viral titer and CTLA4 scAb amount was demonstrated. Therefore, studies in our “patient-like” humanized tumor mouse model allow the exploration of newly designed therapy strategies considering the complex relationships between the developing tumor, the oncolytic virus, and the human immune system. KW - humanized tumor KW - mouse model KW - subcutaneous human tumors KW - Oncolytic vaccinia virus Y1 - 2017 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-170786 VL - 5 ER - TY - JOUR A1 - Tsoneva, Desislava A1 - Stritzker, Jochen A1 - Bedenk, Kristina A1 - Zhang, Qian A1 - Cappello, Joseph A1 - Fischer, Utz A1 - Szalay, Aladar A. T1 - Drug-encoded Biomarkers for Monitoring Biological Therapies JF - PLoS One N2 - Blood tests are necessary, easy-to-perform and low-cost alternatives for monitoring of oncolytic virotherapy and other biological therapies in translational research. Here we assessed three candidate proteins with the potential to be used as biomarkers in biological fluids: two glucuronidases from E. coli (GusA) and Staphylococcus sp. RLH1 (GusPlus), and the luciferase from Gaussia princeps (GLuc). The three genes encoding these proteins were inserted individually into vaccinia virus GLV-1h68 genome under the control of an identical promoter. The three resulting recombinant viruses were used to infect tumor cells in cultures and human tumor xenografts in nude mice. In contrast to the actively secreted GLuc, the cytoplasmic glucuronidases GusA and GusPlus were released into the supernatants only as a result of virus-mediated oncolysis. GusPlus resulted in the most sensitive detection of enzyme activity under controlled assay conditions in samples containing as little as 1 pg/ml of GusPlus, followed by GusA (25 pg/ml) and GLuc (≥375 pg/ml). Unexpectedly, even though GusA had a lower specific activity compared to GusPlus, the substrate conversion in the serum of tumor-bearing mice injected with the GusA-encoding virus strains was substantially higher than that of GusPlus. This was attributed to a 3.2 fold and 16.2 fold longer half-life of GusA in the blood stream compared to GusPlus and GLuc respectively, thus a more sensitive monitor of virus replication than the other two enzymes. Due to the good correlation between enzymatic activity of expressed marker gene and virus titer, we conclude that the amount of the biomarker protein in the body fluid semiquantitatively represents the amount of virus in the infected tumors which was confirmed by low light imaging. We found GusA to be the most reliable biomarker for monitoring oncolytic virotherapy among the three tested markers. KW - mouse models KW - vaccinia virus KW - luciferase KW - biomarkers KW - cytolysis KW - viral replication KW - cell cultures KW - blood Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125265 VL - 10 IS - 9 ER - TY - THES A1 - Veepaschit, Jyotishman T1 - Identification and structural analysis of the Schizosaccharomyces pombe SMN complex T1 - Identifizierung und Strukturanalyse des Schizosaccharomyces pombe SMN-Komplex N2 - The biogenesis of spliceosomal UsnRNPs is a highly elaborate cellular process that occurs both in the nucleus and the cytoplasm. A major part of the process is the assembly of the Sm-core particle, which consists of a ring shaped heptameric unit of seven Sm proteins (SmD1•D2•F•E•G•D3•B) wrapped around a single stranded RNA motif (termed Sm-site) of spliceosomal UsnRNAs. This process occurs mainly in the cytoplasm by the sequential action of two biogenesis factors united in PRMT5- and SMN-complexes, respectively. The PRMT5-complex composed of the three proteins PRMT5, WD45 and pICln is responsible for the symmetric dimethylation of designated arginine residues in the C-terminal tails of some Sm proteins. The action of the PRMT5- complex results in the formation of assembly incompetent Sm-protein intermediates sequestered by the assembly chaperone pICln (SmD1•D2•F•E•G•pICln and pICln•D3•B). Due to the action of pICln, the Sm proteins in these complexes fail to interact with UsnRNAs to form the mature Sm-core. This kinetic trap is relieved by the action of the SMN-complex, which removes the pICln subunit and facilitates the binding of the Sm-core intermediates to the UsnRNA, thus forming the mature Sm-core particle. The human SMN complex consists of 9 subunits termed SMN, Gemin2-8 and Unrip. So far, there are no available atomic structures of the whole SMN-complex, but structures of isolated domains and subunits of the complex have been reported by several laboratories in the past years. The lack of structural information about the entire SMN complex most likely lies in the biophysical properties of the SMN complex, which possesses an oligomeric SMN core, and many unstructured and flexible regions. These were the biggest roadblocks for its structural elucidation using traditional methods such as X-ray crystallography, NMR or CryoEM. To circumvent these obstacles and to obtain structural insight into the SMN-complex, the Schizosaccharomyces pombe SMN complex was used as a model system in this work. In a collaboration with the laboratory of Dr. Remy Bordonne (IGMM, CNRS, France), we could show that the SpSMN complex is minimalistic in its composition, consisting only of SpSMN, SpGemin2, SpGemin8, SpGemin7 and SpGemin6. Using biochemical experiments, an interaction map of the SpSMN complex was established which was found to be highly similar to the reported map of the human SMN complex. The results of this study clearly show that SpSMN is the oligomeric core of the complex and provides the binding sites for the rest of the subunits. Through biochemical and X-ray scattering experiments, the properties of the SpSMN subunit such as oligomerization viii and intrinsic disorder, were shown to determine the overall biophysical characteristics of the whole complex. The structural basis of SpSMN oligomerization is presented in atomic detail which establishes a dimeric SpSMN as the fundamental unit of higher order SpSMN oligomers. In addition to oligomerization, the YG-box domain of SpSMN serves as the binding site for SpGemin8. The unstructured region of SpSMN imparts an unusual large hydrodynamic size, intrinsic disorder, and flexibility to the whole complex. Interestingly, these biophysical properties are partially mitigated by the presence of SpGemin8•SpGemin7•SpGemin6 subunits. These results classify the SpSMN complex as a multidomain entity connected with flexible linkers and characterize the SpSMN subunit to be the central oligomeric structural organizer of the whole complex. N2 - Die Biogenese von spliceosomalen UsnRNPs ist ein hochkomplexer zellulärer Prozess, der sowohl im Zellkern als auch im Zytoplasma stattfindet. Ein Hauptteil dieses Prozesses ist der Aufbau des Sm-Kernpartikels, der aus einem ringförmigen Heptamer aus sieben Sm-Proteinen (SmD1 · D2 · F · E · G · D3 · B) besteht, die um ein einzelsträngiges RNA-Motiv (das auch als Sm-Stelle bezeichnet wird) der spliceosomalen U snRNAs gewickelt ist. Dieser Prozess findet hauptsächlich im Zytoplasma durch die sequenzielle Wirkung von zwei Biogenesefaktoren statt, den PRMT5 und den SMN-Komplexen. Der PRMT5-Komplex besteht aus den drei Proteinen PRMT5, WD45 und pICln und ist für die symmetrische Dimethylierung bestimmter Argininreste in den C-terminalen Schwänzen einiger Sm-Proteine verantwortlich. Die Wirkung des PRMT5-Komplexes führt zur Bildung von inkompetenten Sm-Protein-Intermediaten, die durch das Assemblierungs-Chaperon pICln (SmD1 · D2 · F · E · G · pICln und pICln · D3 · B) sequestriert werden. Aufgrund der Wirkung von pICln interagieren die Sm-Proteine in diesen Komplexen nicht mit den U snRNAs, um den reifen Sm-Kern zu bilden. Diese kinetische Falle wird durch die Wirkung des SMN-Komplexes aufgelöst, der die pICln-Untereinheit entfernt und die Bindung der Sm-Core-Zwischenprodukte an die U snRNA erleichtert, wodurch der reife Sm-Core-Partikel gebildet wird. Der menschliche SMN-Komplex besteht aus 9 Untereinheiten, die als SMN, Gemin2-8 und Unrip bezeichnet werden. Bisher sind keine atomaren Strukturen des gesamten SMN-Komplexes verfügbar, aber Strukturen isolierter Domänen und Untereinheiten des Komplexes wurden in den letzten Jahren von mehreren Laboratorien beschrieben. Der Mangel an strukturellen Informationen über den gesamten SMN-Komplex liegt höchstwahrscheinlich in den biophysikalischen Eigenschaften des SMN-Komplexes, der einen oligomeren SMN-Kern und viele unstrukturierte und flexible Regionen besitzt. Dies waren die größten Hindernisse für die Strukturaufklärung mit traditionellen Methoden wie Röntgenkristallographie, NMR oder CryoEM. Um diese Hindernisse zu umgehen und strukturelle Einblicke in den SMN-Komplex zu erhalten, wurde in dieser Arbeit der SMN-Komplex von Schizosaccharomyces pombe als Modellsystem verwendet. In Zusammenarbeit mit dem Labor von Dr. Remy Bordonne (IGMM, CNRS, Frankreich) konnten wir zeigen, dass der SpSMN-Komplex in seiner Zusammensetzung minimalistisch ist und nur aus SpSMN, SpGemin2, SpGemin8, SpGemin7 und SpGemin6 besteht. Mit biochemischer Experimenten wurde eine x Interaktionskarte des SpSMN-Komplexes erstellt, die der bekannten Karte des menschlichen SMN-Komplexes sehr ähnlich war. Die Ergebnisse dieser Studie zeigen deutlich, dass SpSMN der oligomere Kern des Komplexes ist und die Bindungsstellen für den Rest der Untereinheiten bereitstellt. Durch biochemische und Röntgenstreuungsexperimente wurde gezeigt, dass die Eigenschaften der SpSMNUntereinheit wie Oligomerisierung und intrinsische Störung die gesamten biophysikalischen Eigenschaften des gesamten Komplexes bestimmen. Die strukturelle Basis der SpSMN-Oligomerisierung wird atomar detailliert dargestellt, wodurch ein dimeres SpSMN als zentrale Grundeinheit der SpSMN-Oligomere höherer Ordnung festgelegt wird. Zusätzlich zur Oligomerisierung dient die YG-Box- Domäne von SpSMN als Bindungsstelle für SpGemin8. Die unstrukturierte Region von SpSMN verleiht dem gesamten Komplex eine ungewöhnlich große hydrodynamische Größe, intrinsische Unordnung und Flexibilität. Interessanterweise werden diese biophysikalischen Eigenschaften teilweise durch das Vorhandensein von SpGemin8 • SpGemin7 • SpGemin6-Untereinheiten gemindert. Diese Ergebnisse klassifizieren den SpSMN-Komplex als eine mit flexiblen Wechselwirkungen verbundene Multidomäneneinheit und charakterisieren die SpSMN-Untereinheit als den zentralen oligomeren Strukturorganisator des gesamten Komplexes. KW - Multiproteinkomplex KW - Survival Motor Neuron KW - Protein purification KW - X-ray crystallography KW - Small angle X-ray scattering KW - Biogenese KW - Schizosaccharomyces pombe KW - SMN Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-238365 ER - TY - JOUR A1 - Veepaschit, Jyotishman A1 - Viswanathan, Aravindan A1 - Bordonne, Remy A1 - Grimm, Clemens A1 - Fischer, Utz T1 - Identification and structural analysis of the Schizosaccharomyces pombe SMN complex JF - Nucleic Acids Research N2 - The macromolecular SMN complex facilitates the formation of Sm-class ribonucleoproteins involved in mRNA processing (UsnRNPs). While biochemical studies have revealed key activities of the SMN complex, its structural investigation is lagging behind. Here we report on the identification and structural determination of the SMN complex from the lower eukaryote Schizosaccharomyces pombe, consisting of SMN, Gemin2, 6, 7, 8 and Sm proteins. The core of the SMN complex is formed by several copies of SMN tethered through its C-terminal alpha-helices arranged with alternating polarity. This creates a central platform onto which Gemin8 binds and recruits Gemins 6 and 7. The N-terminal parts of the SMN molecules extrude via flexible linkers from the core and enable binding of Gemin2 and Sm proteins. Our data identify the SMN complex as a multivalent hub where Sm proteins are collected in its periphery to allow their joining with UsnRNA. KW - Schizosaccharomyces pombe KW - SMN Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-259880 VL - 49 IS - 13 ER - TY - THES A1 - Vyalkova, Anna T1 - Efficacy of approved Smallpox Vaccines in Human and Canine Cancer Therapy: Adipose - tissue derived Stem Cells (ADSC) take up VACV and serve as a protective vehicle for virus delivery to tumors T1 - Wirksamkeit zugelassener Pockenimpfstoffe in der Krebstherapie bei Menschen und Hunden: Aus Gewebe gewonnene Stammzellen (ADSC) nehmen VACV auf und dienen als schützendes Vehikel für den Viruseintrag in Tumore N2 - Cancer is one of the major causes of mortality in developed countries. In 2020, there were more than 19.3 million new cases of tumor malignancies worldwide, with more than 10 million deaths. The high rates of cancer cases and mortality necessitate extensive research and the development of novel cancer treatments and antitumor agents. In most cases, conventional treatment strategies for tumor therapy are based on chemotherapeutic treatment, which is supplemented with radiotherapy and/or surgical resection of solid tumors [1]. The use of chemotherapy for the treatment of cancer has significant side effects, the most dangerous of which is toxicity [2] [3]. Modern methods of treating tumors focus on specific drug delivery to the tumor site, actively targeting the tumor cells, as well as the reduction of side effects. One of the most promising current approaches is based on oncolytic viruses. Antitumor properties of viruses were documented at the beginning of the 20th century when some cancer patients recovered after acute viral infections, particularly influenza [4]. Vaccinia virus (VACV) is a member of the Poxviridae family, has natural antitumor properties, and provides a good basis for generating efficient recombinant oncolytic strains. Furthermore, VACV has never been shown to integrate into the host genome [5]. VACV is likely one of the safest and well-studied viruses due to extensive research being done in molecular biology and pathophysiology to investigate its potential as a vaccine for smallpox eradication programs. It has been administered to over 200 million people worldwide. VACV antitumor therapeutic effectiveness has been established in xenograft models with a variety of tumor types for human and canine cancers. Furthermore, recombinant oncolytic VACVs expressing genes encoding light-emitting proteins are a big improvement in a treatment strategy that combines tumor-specific therapies and diagnostics. Oncolytic virus treatments are effective in xenograft cancer models in mice, however, the significant improvements found in mice do not always translate to human cancer patients. These therapies should be tested in dogs with spontaneous cancer not only to offer well translatable information regarding the possible efficiency of viral therapy for human cancers but also to improve the health of our household pets as well. Spontaneous canine tumors are starting to be regarded as an essential model of human cancers that can reproduce the tumor microenvironment and immune response of cancer patients [6]. Just as data obtained in dog experiments can improve cancer therapy for human patients, these findings can also be used to improve treatment protocols in canine patients. Hundreds of studies and dozens of reviews have been published regarding the antitumor effects of various recombinants of VACV, but information on the anticancer features of initial, genetically-unmodified “naïve” VACV is still limited. In the first studies, we compared different wild-type, non-modified strains of VACV and tested their oncolytic properties on a panel of various cancer cells derived from different organs. In addition, we also tested a protection system based on the “Trojan horse” concept - using a combination of human Adipose tissue-derived Stem Cells (hADSC) and three different wild-type single plaque purified Vaccinia virus strains: W1, L1, and T1. We showed that all tested human cell lines (FaDu, MDA MB 231, HNT-13, HNT-35, and PC-3) are permissive to L0, W0, T0, L1, W1, and L1 infection. Furthermore, we tested the cytotoxicity of VACV in different cancer cell lines (A549, PC-3, MDA-MB 231, FaDu, HNT-13, HNT-25, and HNT-35). All strains lysed the cells, which was most visible at 96 hpi. We also showed that all tested strains could efficiently infect and multiply in hADSC at a high level. In our in vivo study, we tested the therapeutic efficacy of the wild-type Vaccinia viruses L1, W1, and T1 alone or in combination with hADSC. Wild-type VACV strains were tested for their oncolytic efficiency in human lung adenocarcinoma (A549) in a xenograft model. Treatment of A549 tumors with different doses of L1 and W1 as well as with a L1/ADSC or W1/ADSC combination led to significant tumor regression compared to the PBS control. Additionally, the treatment with L1 and W1 and the combination of L1/ADSC and W1/ADSC was well tolerated by the animals. In the case of the wild-type Tian Tan strain, results were not obtained due to the high cytotoxicity of this strain. Therefore, it should be attenuated for further studies. In the second part of the current study, we investigated the oncolytic effect of C1-opt1, W1 opt1, and L3-opt1 strains based on the wild-type Copenhagen, Wyeth, and Lister vaccines with additional expression of turboFP635. Replication and cytotoxicity assays demonstrated that all 3 viruses were able to infect, replicate in and kill canine tumor cell lines STSA-1 and CT1258 in a virus dose- and time- dependent fashion. Cytotoxicity and replication assays were also performed on cultured canine Adipose-derived Mesenchymal Stem Cells (cAdMSC). The results showed that the cells were lysed much slower than the tumor cells. It suggests that these cells can harbour the virus for a long-term period, allowing the virus to spread into the body and there is enough time to reach the primary tumor or metastases before the cell carrier is destroyed. The viral replication in cAdMSC in our study was lower than in canine cancer cells (STSA-1 and CT1258) at the same MOI. After being studied in cell culture, C1 opt1 and their combination with cAdMSC (C1-opt1/cAdMSC) were used in canine STSA 1 tumor bearing nude mice. We tested the oncolytic effect of the C1-opt1 virus alone and in combination with cAdMSC in the canine STSA-1 xenograft mouse model. Altogether, our findings have shown that both C1-opt1 and cAdMSC/C1-opt1 significantly reduced tumor size or eliminated the tumor. There was no significant difference between C1-opt1 alone and cAdMSC/C1-opt1. The virus particles were mostly found within the tumor after 24 dpi, some amount of virus particles were found in the lungs of mice injected with a combination of cAdMSC/C1-opt1 but not in the group injected with virus alone (cAdMSC might get stuck in the lungs and cause virus propagation there). Taken together, this study provided a proof-of-concept that hADSC/cAdMSC can be used as a carrier system for the “Trojan horse” concept. However, it should be confirmed in another experimental model system, such as canine patients. Moreover, these findings suggest that wild-type, non-modified strains of Vaccinia virus isolates can be considered promising candidates for oncolytic virotherapy, especially in combination with mesenchymal stem cells. N2 - Krebs wird zu einer der Hauptursachen für die Sterblichkeit in den Industrieländern. Im Jahr 2020 gab es weltweit mehr als 193 Millionen neue Fälle von tumormalen Erkrankungen mit mehr als 10 Millionen Todesfällen. Folglich erfordern die hohen Krebsfälle- und Mortalitätsraten umfangreiche Forschung und Entwicklung neuartiger Krebsbehandlungen und Antitumormittel. Konventionelle Behandlungsstrategien zur Tumortherapie basieren in den meisten Fällen auf einer chemotherapeutischen Behandlung, die durch Strahlentherapie und/oder chirurgische Resektion solider Tumoren ergänzt wird [1]. Die Verwendung von Chemotherapie zur Behandlung von Krebs hat erhebliche Nebenwirkungen, insbesondere die gefährlichste Intoxikation [2] [3]. ... KW - ADSC KW - AdMSC KW - Vaccinia virus (VACV) Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-253457 ER - TY - JOUR A1 - Waldholm, Johan A1 - Wang, Zhi A1 - Brodin, David A1 - Tyagi, Anu A1 - Yu, Simei A1 - Theopold, Ulrich A1 - Östlund Farrants, Ann Kristin A1 - Visa, Neus T1 - SWI/SNF regulates the alternative processing of a specific subset of pre-mRNAs in \(Drosophila\) \(melanogaster\) JF - BMC Molecular Biology N2 - Background: The SWI/SNF chromatin remodeling factors have the ability to remodel nucleosomes and play essential roles in key developmental processes. SWI/SNF complexes contain one subunit with ATPase activity, which in Drosophila melanogaster is called Brahma (Brm). The regulatory activities of SWI/SNF have been attributed to its influence on chromatin structure and transcription regulation, but recent observations have revealed that the levels of Brm affect the relative abundances of transcripts that are formed by alternative splicing and/or polyadenylation of the same pre-mRNA. Results: We have investigated whether the function of Brm in pre-mRNA processing in Drosophila melanogaster is mediated by Brm alone or by the SWI/SNF complex. We have analyzed the effects of depleting individual SWI/SNF subunits on pre-mRNA processing throughout the genome, and we have identified a subset of transcripts that are affected by depletion of the SWI/SNF core subunits Brm, Snr1 or Mor. The fact that depletion of different subunits targets a subset of common transcripts suggests that the SWI/SNF complex is responsible for the effects observed on pre-mRNA processing when knocking down Brm. We have also depleted Brm in larvae and we have shown that the levels of SWI/SNF affect the pre-mRNA processing outcome in vivo. Conclusions: We have shown that SWI/SNF can modulate alternative pre-mRNA processing, not only in cultured cells but also in vivo. The effect is restricted to and specific for a subset of transcripts. Our results provide novel insights into the mechanisms by which SWI/SNF regulates transcript diversity and proteomic diversity in higher eukaryotes. KW - Chromatin-remodeling complexes KW - In-vivo KW - Genes KW - Distinct KW - Brahma KW - Transcription KW - Trithorax KW - Subunit KW - Exons KW - BRM Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142613 VL - 12 IS - 46 ER - TY - JOUR A1 - Wang, Huiqiang A1 - Chen, Nanhai G. A1 - Minev, Boris R. A1 - Szalay, Aladar A. T1 - Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells JF - Journal of Translational Medicine N2 - Background: Recent data suggest that cancer stem cells (CSCs) play an important role in cancer, as these cells possess enhanced tumor-forming capabilities and are responsible for relapses after apparently curative therapies have been undertaken. Hence, novel cancer therapies will be needed to test for both tumor regression and CSC targeting. The use of oncolytic vaccinia virus (VACV) represents an attractive anti-tumor approach and is currently under evaluation in clinical trials. The purpose of this study was to demonstrate whether VACV does kill CSCs that are resistant to irradiation and chemotherapy. Methods: Cancer stem-like cells were identified and separated from the human breast cancer cell line GI-101A by virtue of increased aldehyde dehydrogenase 1 (ALDH1) activity as assessed by the ALDEFLUOR assay and cancer stem cell-like features such as chemo-resistance, irradiation-resistance and tumor-initiating were confirmed in cell culture and in animal models. VACV treatments were applied to both ALDEFLUOR-positive cells in cell culture and in xenograft tumors derived from these cells. Moreover, we identified and isolated CD44\(^+\)CD24\(^+\)ESA\(^+\) cells from GI-101A upon an epithelial-mesenchymal transition (EMT). These cells were similarly characterized both in cell culture and in animal models. Results: We demonstrated for the first time that the oncolytic VACV GLV-1h68 strain replicated more efficiently in cells with higher ALDH1 activity that possessed stem cell-like features than in cells with lower ALDH1 activity. GLV-1h68 selectively colonized and eventually eradicated xenograft tumors originating from cells with higher ALDH1 activity. Furthermore, GLV-1h68 also showed preferential replication in CD44\(^+\)CD24\(^+\)ESA\(^+\) cells derived from GI-101A upon an EMT induction as well as in xenograft tumors originating from these cells that were more tumorigenic than CD44\(^+\)CD24\(^-\)ESA\(^+\) cells. Conclusions: Taken together, our findings indicate that GLV-1h68 efficiently replicates and kills cancer stem-like cells. Thus, GLV-1h68 may become a promising agent for eradicating both primary and metastatic tumors, especially tumors harboring cancer stem-like cells that are resistant to chemo and/or radiotherapy and may be responsible for recurrence of tumors. KW - tumors KW - therapy KW - metastasis KW - identification KW - lines KW - gene expression KW - in-vitro propagation KW - acute myeloid leukemia KW - epithelial-mesenchymal transition KW - subpopulation Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130019 VL - 10 IS - 167 ER - TY - JOUR A1 - Wang, Huiqiang A1 - Chen, Nanhai G. A1 - Minev, Boris R. A1 - Zimmermann, Martina A1 - Aguilar, Richard J. A1 - Zhang, Qian A1 - Sturm, Julia B. A1 - Fend, Falko A1 - Yu, Yong A. A1 - Cappello, Joseph A1 - Lauer, Ulrich M. A1 - Szalay, Aladar A. T1 - Optical Detection and Virotherapy of Live Metastatic Tumor Cells in Body Fluids with Vaccinia Strains JF - PLoS ONE N2 - Metastatic tumor cells in body fluids are important targets for treatment, and critical surrogate markers for evaluating cancer prognosis and therapeutic response. Here we report, for the first time, that live metastatic tumor cells in blood samples from mice bearing human tumor xenografts and in blood and cerebrospinal fluid samples from patients with cancer were successfully detected using a tumor cell-specific recombinant vaccinia virus (VACV). In contrast to the FDA-approved CellSearch system, VACV detects circulating tumor cells (CTCs) in a cancer biomarker-independent manner, thus, free of any bias related to the use of antibodies, and can be potentially a universal system for detection of live CTCs of any tumor type, not limited to CTCs of epithelial origin. Furthermore, we demonstrate for the first time that VACV was effective in preventing and reducing circulating tumor cells in mice bearing human tumor xenografts. Importantly, a single intra-peritoneal delivery of VACV resulted in a dramatic decline in the number of tumor cells in the ascitic fluid from a patient with gastric cancer. Taken together, these results suggest VACV to be a useful tool for quantitative detection of live tumor cells in liquid biopsies as well as a potentially effective treatment for reducing or eliminating live tumor cells in body fluids of patients with metastatic disease. KW - lymph nodes KW - cancer treatment KW - metastatic tumors KW - breast cancer KW - blood KW - prostate cancer KW - ascites KW - mouse models Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130059 VL - 8 IS - 9 ER - TY - THES A1 - Wanzek, Katharina T1 - The investigation of the function of repair proteins at G-quadruplex structures in \(Saccharomyces\) \(cerevisiae\) revealed that Mms1 promotes genome stability T1 - Die Untersuchung der Funktion von Reparaturproteinen an G-Quadruplex Strukturen in \(Saccharomyces\) \(cerevisiae\) zeigte, dass Mms1 Genomstabilität fördert N2 - G-quadruplex structures are highly stable alternative DNA structures that can, when not properly regulated, impede replication fork progression and cause genome instability (Castillo Bosch et al, 2014; Crabbe et al, 2004; Koole et al, 2014; Kruisselbrink et al, 2008; London et al, 2008; Lopes et al, 2011; Paeschke et al, 2013; Paeschke et al, 2011; Piazza et al, 2015; Piazza et al, 2010; Piazza et al, 2012; Ribeyre et al, 2009; Sabouri et al, 2014; Sarkies et al, 2012; Sarkies et al, 2010; Schiavone et al, 2014; Wu & Spies, 2016; Zimmer et al, 2016). The aim of this thesis was to identify novel G-quadruplex interacting proteins in Saccharomyces cerevisiae and to unravel their regulatory function at these structures to maintain genome integrity. Mms1 and Rtt101 were identified as G-quadruplex binding proteins in vitro via a pull-down experiment with subsequent mass spectrometry analysis. Rtt101, Mms1 and Mms22, which are all components of an ubiquitin ligase (Rtt101Mms1/Mms22), are important for the progression of the replication fork following fork stalling (Luke et al, 2006; Vaisica et al, 2011; Zaidi et al, 2008). The in vivo binding of endogenously tagged Mms1 to its target regions was analyzed genome-wide using chromatin-immunoprecipitation followed by deep-sequencing. Interestingly, Mms1 bound independently of Mms22 and Rtt101 to G-rich regions that have the potential to form G-quadruplex structures. In vitro, formation of G-quadruplex structures could be shown for the G-rich regions Mms1 bound to. This binding was observed throughout the cell cycle. Furthermore, the deletion of MMS1 caused replication fork stalling as evidenced by increased association of DNA Polymerase 2 at Mms1 dependent sites. A gross chromosomal rearrangement assay revealed that deletion of MMS1 results in a significantly increased genome instability at G-quadruplex motifs compared to G-rich or non-G-rich regions. Additionally, binding of the helicase Pif1, which unwinds G4 structures in vitro (Paeschke et al, 2013; Ribeyre et al, 2009; Sanders, 2010; Wallgren et al, 2016), to Mms1 binding sites was reduced in mms1 cells. The data presented in this thesis, together with published data, suggests a novel mechanistic model in which Mms1 binds to G-quadruplex structures and enables Pif1 association. This allows for replication fork progression and genome integrity. N2 - Bei G-quadruplex Strukturen handelt es sich um stabile Sekundärstrukturen der DNA, welche das Fortschreiten der Replikationsgabel behindern und Genominstabilität verursachen können, falls sie nicht konsequent reguliert werden (Castillo Bosch et al, 2014; Crabbe et al, 2004; Koole et al, 2014; Kruisselbrink et al, 2008; London et al, 2008; Lopes et al, 2011; Paeschke et al, 2013; Paeschke et al, 2011; Piazza et al, 2015; Piazza et al, 2010; Piazza et al, 2012; Ribeyre et al, 2009; Sabouri et al, 2014; Sarkies et al, 2012; Sarkies et al, 2010; Schiavone et al, 2014; Wu & Spies, 2016; Zimmer et al, 2016). Ziel dieser Doktorarbeit war es, neue Proteininteraktionspartner dieser Strukturen in Saccharomyces cerevisiae zu identifizieren und zu untersuchen, wie diese Proteine die Strukturen regulieren um Genomstabilität zu gewährleisten. Mit Hilfe eines Pulldown Assays und anschließender massenspektrometrischer Analyse wurden Mms1 und Rtt101 in vitro als Interaktionspartner von G-quadruplex Strukturen identifiziert. Rtt101, Mms1 und Mms22, Komponenten der Ubiquitinligase Rtt101Mms1/Mms22, spielen eine wichtige Rolle beim Fortschreiten der Replikationsgabel, falls dieses durch Agenzien gehemmt wurde (Luke et al, 2006; Vaisica et al, 2011; Zaidi et al, 2008). Durch Chromatin-Immunpräzipitation mit anschließender Hochdurchsatzsequenzierung wurden die Bindestellen von Mms1 identifiziert. Interessanterweise hat Mms1 genomweit an G-reiche Sequenzen gebunden. Diese G-reichen Sequenzen bildeten G-quadruplex Strukturen in vitro aus. Die Bindung von Mms1 erfolgte unabhängig von Rtt101 und Mms22 sowie während des gesamten Zellzyklus. Außerdem kam es zu einer Verlangsamung der Replikationsgabel in mms1 Zellen, was durch eine verstärkte Bindung der DNA Polymerase 2 nachgewiesen wurde. Ein gross chromsomal rearrangement assay zeigte, dass die Genominstabilität in mms1 Zellen signifikant erhöht ist, wenn G-quadruplex Motive, im Vergleich zu nicht-G-reichen oder G-reichen Kontrollregionen, vorhanden sind. Zudem war die Bindung der Helikase Pif1, welche G-quadruplex Strukturen in vitro entwindet (Paeschke et al, 2013; Ribeyre et al, 2009; Sanders, 2010; Wallgren et al, 2016), stark reduziert, wenn Mms1 fehlte. Mit Hilfe der in dieser Doktorarbeit gewonnenen Ergebnisse, sowie mit Hilfe publizierter Daten, lässt sich ein Model postulieren, in welchem Mms1 an G-quadruplexe bindet und somit die Bindung von Pif1 ermöglicht. Dadurch werden das Fortschreiten der Replikationsgabel und die Genomstabilität gewährleistet. KW - Quadruplex-DNS KW - DNS-Reparatur KW - genome stability KW - Bierhefe Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-142547 ER - TY - JOUR A1 - Weibel, Stephanie A1 - Basse-Luesebrink, Thomas Christian A1 - Hess, Michael A1 - Hofmann, Elisabeth A1 - Seubert, Carolin A1 - Langbein-Laugwitz, Johanna A1 - Gentschev, Ivaylo A1 - Sturm, Volker Jörg Friedrich A1 - Ye, Yuxiang A1 - Kampf, Thomas A1 - Jakob, Peter Michael A1 - Szalay, Aladar A. T1 - Imaging of Intratumoral Inflammation during Oncolytic Virotherapy of Tumors by \(^{19}\)F-Magnetic Resonance Imaging (MRI) JF - PLoS ONE N2 - Background Oncolytic virotherapy of tumors is an up-coming, promising therapeutic modality of cancer therapy. Unfortunately, non-invasive techniques to evaluate the inflammatory host response to treatment are rare. Here, we evaluate \(^{19}\)F magnetic resonance imaging (MRI) which enables the non-invasive visualization of inflammatory processes in pathological conditions by the use of perfluorocarbon nanoemulsions (PFC) for monitoring of oncolytic virotherapy. Methodology/Principal Findings The Vaccinia virus strain GLV-1h68 was used as an oncolytic agent for the treatment of different tumor models. Systemic application of PFC emulsions followed by \(^1H\)/\(^{19}\)F MRI of mock-infected and GLV-1h68-infected tumor-bearing mice revealed a significant accumulation of the \(^{19}\)F signal in the tumor rim of virus-treated mice. Histological examination of tumors confirmed a similar spatial distribution of the \(^{19}\)F signal hot spots and \(CD68^+\)-macrophages. Thereby, the \(CD68^+\)-macrophages encapsulate the GFP-positive viral infection foci. In multiple tumor models, we specifically visualized early inflammatory cell recruitment in Vaccinia virus colonized tumors. Furthermore, we documented that the \(^{19}\)F signal correlated with the extent of viral spreading within tumors. Conclusions/Significance These results suggest \(^{19}\)F MRI as a non-invasive methodology to document the tumor-associated host immune response as well as the extent of intratumoral viral replication. Thus, \(^{19}\)F MRI represents a new platform to non-invasively investigate the role of the host immune response for therapeutic outcome of oncolytic virotherapy and individual patient response. KW - inflammation KW - fluorescence microscopy KW - oncolytic viruses KW - fluorescence imaging KW - macrophages KW - magnetic resonance imaging KW - histology KW - in vivo imaging Y1 - 2013 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130311 VL - 8 IS - 3 ER - TY - THES A1 - Wollny, Claudia T1 - Der p97-Kofaktor UBXD1 ist ein neuer Regulator des NF-kB-Signalweges T1 - The p97-cofactor UBXD1 is a new regulator of NF-kB-signaling N2 - Die essenzielle, Ubiquitin-selektive ATPase p97 reguliert eine Vielzahl unterschiedlicher Prozesse in Eukaryoten. Dazu zählen Proteinqualitätskontrolle, DNA-Reparatur, Signaltransduktion, Zellzykluskontrolle, Autophagie sowie das endolysosomale System. Diese unterschiedlichen Funktionen von p97 werden durch die Bindung von Kofaktoren engmaschig gesteuert und kontrolliert. Die größte und am besten untersuchte Gruppe von p97-Kofaktoren sind die Proteine der UBX Familie. Diese zeichnen sich durch den Besitz einer UBX-Domäne aus, welche die Bindung an p97 vermittelt. Das in höheren Eukaryoten konservierte Familienmitglied UBXD1 besitzt darüber hinaus mit einer PUB-Domäne und einem VIM-Motiv noch mindestens zwei weitere p97-Bindemodule. UBXD1 kann an Vesikel des endolysosomalen Degradationssytems lokalisieren, seine genauen zellulären Funktionen sind jedoch noch weitgehend unbekannt. Ziel dieser Arbeit war die funktionelle Charakterisierung von humanem UBXD1. Dafür wurden Kandidaten eines zuvor durchgeführten Yeast-Two-Hybrid-Screens auf ihre Two Hybrid-Interaktion mit unterschiedlichen UBXD1-Varianten getestet. Darüber hinaus wurde durch Immunpräzipitationsexperimente untersucht, ob die Kandidatenproteine auch in Säugerzellen mit UBXD1 interagieren. Als vielversprechende neue Bindungspartner von UBXD1 wurden so die Ubiquitin-Ligase TRIAD3A und das Ubiquitin-editierende Protein A20 identifiziert. Desweiteren konnte gezeigt werden, dass die Interaktion zwischen UBXD1 und A20 von einer funktionellen PUB Domäne und dem siebten Zinkfinger Motiv von A20 abhängig ist. Da sowohl TRIAD3A als auch A20 negative Regulatoren des NF B Signalweges sind, wurde daraufhin untersucht, ob auch UBXD1 eine Funktion in diesem Signalweg besitzt. Tatsächlich war in UBXD1-depletierten HeLa 57A-Zellen die NF B-abhängige Expression eines Reportgens nach Aktivierung des Signalweges durch TNF, IL-1, Doxorubicin und H2O2 stark reduziert. Dabei spricht die verringerte Aktivierung nach unterschiedlichen Stimuli für eine generelle Rolle von UBXD1 im NF B Signalweg. Durch quantitative Echtzeit-PCR konnte gezeigt werden, dass in HeLa- und HEK293T-Zellen nach UBXD1-Depletion auch die Expression endogener NF B Zielgene verringert ist. Da in UBXD1-depletierten Zellen nach Stimulation mit TNF oder IL-1 bereits die Kerntranslokation des NF B-Transkriptionsfaktor p65 reduziert ist, ist davon auszugehen, dass UBXD1 an einer früheren Phase der Aktivierung des Signalweges beteiligt ist. Möglicherweise ist dies darauf zurückzuführen, dass UBXD1 bekannte Funktionen von A20 reguliert und etwa die Bindung von A20 an Vesikel des endolysosomalen Systems oder an lineare Ubiquitinketten beeinflusst. Diese Arbeit beschreibt somit eine neue Funktion des p97-Kofaktors UBXD1 im NF B-Signalweg. N2 - The essential, ubiquitin-selective ATPase p97 regulates a variety of cellular processes in eukaryotes. Among others, these include protein quality control, DNA repair, signal-transduction, cell cycle control, autophagy and the endolysosomal system. The distinct functions of p97 are tightly controlled by regulatory cofactors. UBX domain-containing proteins are the largest and best studied group of p97 cofactors . They are characterized by a UBX domain, which mediates binding to p97. The family-member UBXD1 is highly conserved in higher eukaryotes and possesses at least two additional p97 binding modules, a PUB domain and a VIM motif. While UBXD1 can localize to vesicles of the endolysosomal degradation system, its exact cellular function is still poorly understood. The aim of this study was the functional characterisation of human UBXD1. To that end, candidates of a previous yeast two-hybrid screen were tested for their two-hybrid interaction with different UBXD1 variants. Immunoprecipitation experiments were used to analyse if the candidates also interact with UBXD1 in mammalian cells. This led to the identification of the ubiquitin-ligase TRIAD3A and the ubiquitin-editing protein A20 as promising new binding partners of UBXD1. Moreover, it could be demonstrated that the interaction between UBXD1 and A20 depends on a functional PUB domain and the seventh zinc finger motif of A20. Because both TRIAD3A and A20 are negative regulators of the NF-B signaling pathway, it was subsequently tested if UBXD1 also has a function in NF-B signaling. Indeed, UBXD1-depleted HeLa 57A cells showed a strongly reduced NF B dependent expression of a reporter gene after activation of the signaling pathway by TNF, IL-1, Doxorubicin and H2O2. The reduced activity observed after various stimuli argues for a general role of UBXD1 in the NF-B signaling pathway. Quantitative real-time PCR demonstrated that the expression of endogenous NF-B target genes in HeLa and HEK293T cells was also reduced upon UBXD1-depletion. Since the nuclear translocation of the NF-B subunit p65 upon stimulation with TNF or IL-1was also reduced in UBXD1-depleted cells, UBXD1 is likely to participate in an earlier phase of NF-B activation. It is possible that UBXD1 regulates a known function of A20 and influences for example the binding of A20 to endocytic vesicles or to linear ubiquitin chains. In summary, this work describes a novel function of the p97 cofactor UBXD1 as a positive regulator of the NF-B signaling pathway. KW - Ubiquitin KW - UBXD1 KW - Signaltransduktion KW - Cofaktor KW - p97 KW - Signalweg KW - Zellbiologie Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132430 ER - TY - THES A1 - Ye, Mingyu T1 - Immunotherapy with Vaccinia virus co-expressing tumor-associated antigens and mouse IL-2 cytokine in mice with mammary cancer T1 - Immuntherapie von Brustkrebs in tumortragenden Mäusen mit genetisch modifizierten Vaccinia Viren, die simultan Interleukin-2 und tumorassoziierte Antigene exprimieren N2 - Interleukin 2 (IL-2) was the first cytokine applied for cancer treatment in human history. It has been approved as monotherapy for renal cell carcinoma and melanoma by the FDA and does mediate the regression of the tumors in patients. One of the possible mechanisms is that the administration of IL-2 led to T lymphocytes expansion, including CD4+ and CD8+ T cells. In addition, a recent study demonstrated that antigen-specific T cells could also be expanded through the induction of IL-2, which plays a crucial role in mediating tumor regression. However, despite the long-term and extensive use of IL-2 in the clinic, the ratio of patients who get a complete response was still low, and only about one-fifth of patients showed objective tumor regression. Therefore, the function of IL-2 in cancer treatment should continue to be optimized and investigated. A study by Franz O. Smith et al. has shown that the combination treatment of IL-2 and tumor-associated antigen vaccine has a strong trend to increased objective responses compared to patients with melanoma receiving IL-2 alone. Peptide vaccines are anti-cancer vaccines able to induce a powerful tumor antigenspecific immune response capable of eradicating the tumors. According to the type of antigens, peptide vaccines can be classified into two distinct categories: Tumor-associated antigens (TAA) vaccine and tumor-specific neoantigens (TSA) vaccine. Currently, Peptide vaccines are mainly investigated in phase I and phase II clinical trials of human cancer patients with various advanced cancers such as lung cancer, gastrointestinal tumors, and breast cancers. Vaccinia virus (VACV) is one of the safest viral vectors, which has been wildly used in cancer treatment and pathogen prevention. As an oncolytic vector, VACV can carry multiple large foreign genes, which enable the virus to introduce diagnostic and therapeutic agents without dramatically reducing the viral replication. Meanwhile, the recombinant vaccinia virus (rVACV) can be easily generated by homologous recombination. Here, we used the vaccinia virus as the therapeutic cancer vector, expressing mouse Interleukin 2 (IL-2) and tumor-associated antigens simultaneously to investigate the combined effect of anti-tumor immune response in the 4T1 mouse tumor model. As expected, the VACV driven mIL-2 expression remarkably increased both CD4+ and CD8+ populations in vivo, and the virus-expressed tumor-associated peptides successfully elicited theantigen-specific T cell response to inhibit the growth of tumors. Furthermore, the experiments with tumor-bearing animals showed that the mIL-2 plus tumor antigens expressing VACV vector gave a better anti-cancer response than the mIL-2 alone expressing vector. The combinations did significantly more inhibit tumor growth than mIL-2 treatment alone. Moreover, the results confirmed our previous unpublished data that the mIL-2 expression driven by synthetic early/late promoter in the Lister strain VACV could enhance the tumor regression in the 4T1 mouse model. N2 - Interleukin 2 (IL-2) war das erste Zytokin in der Geschichte des Menschen, das zur Krebsbehandlung eingesetzt wurde. Es ist von der FDA als Monotherapie für Nierenzellkarzinome und Melanome zugelassen und kann bei Patienten die Rückbildung von Tumorerkrankungen fördern. Einer der möglichen Mechanismen ist, dass die Verabreichung von IL-2 zu einer T-Zell- Expansion führte. Darüber hinaus zeigte eine aktuelle Studie, dass auch antigenspezifische T- Zellen vermehrt werden können, was eine entscheidende Rolle bei der Vermittlung der Tumorregression spielt. Trotz des langjährigen und umfangreichen Einsatzes von IL-2 in der Klinik war der Anteil der Patienten, die eine komplette Antwort Zeigten, jedoch immer noch gering, und nur etwa ein Fünftel der Patienten weist eine objektive Tumorregression auf. Daher sollte die Funktion von IL-2 in der Krebsbehandlung weiter optimiert und untersucht werden. Eine Studie von Franz O. Smith et al. hat gezeigt, dass die Kombinationsbehandlung von IL-2 und tumorassoziiertem Antigenimpfstoff im Vergleich zu Melanomapatienten, die IL-2 allein erhalten, einen starken Trend zu verstärkten objektiven Reaktionen aufweist. Peptidimpfstoff ist ein Anti- Krebs-Impfstoff, der in der Lage ist, eine starke tumorantigenspezifische Immunantwort zu induzieren, die die Tumore ausrotten kann. Je nach Art der Antigene kann es in zwei verschiedene Kategorien eingeteilt werden: Impfstoff gegen tumorassoziierte Antigene (TAA) und Impfstoff gegen tumorspezifische Neoantigene (TSA). Derzeit werden Peptidimpfstoffe hauptsächlich in klinischen Studien in Phasen I und II an Patienten mit verschiedenen fortgeschrittenen Krebsarten wie Lungenkrebs, Magen-Darm-Tumoren und Brustkrebs untersucht ... KW - Immunotherapy KW - Vaccinia virus Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-253095 ER - TY - JOUR A1 - Yin, Jun A1 - Brocher, Jan A1 - Fischer, Utz A1 - Winkler, Christoph T1 - Mutant Prpf31 causes pre-mRNA splicing defects and rod photoreceptor cell degeneration in a zebrafish model for Retinitis pigmentosa JF - Molecular neurodegeneration N2 - Background: Retinitis pigmentosa (RP) is an inherited eye disease characterized by the progressive degeneration of rod photoreceptor cells. Mutations in pre-mRNA splicing factors including PRPF31 have been identified as cause for RP, raising the question how mutations in general factors lead to tissue specific defects. Results: We have recently shown that the zebrafish serves as an excellent model allowing the recapitulation of key events of RP. Here we use this model to investigate two pathogenic mutations in PRPF31, SP117 and AD5, causing the autosomal dominant form of RP. We show that SP117 leads to an unstable protein that is mislocalized to the rod cytoplasm. Importantly, its overexpression does not result in photoreceptor degeneration suggesting haploinsufficiency as the underlying cause in human RP patients carrying SP117. In contrast, overexpression of AD5 results in embryonic lethality, which can be rescued by wild-type Prpf31. Transgenic retina-specific expression of AD5 reveals that stable AD5 protein is initially localized in the nucleus but later found in the cytoplasm concurrent with progressing rod outer segment degeneration and apoptosis. Importantly, we show for the first time in vivo that retinal transcripts are wrongly spliced in adult transgenic retinas expressing AD5 and exhibiting increased apoptosis in rod photoreceptors. Conclusion: Our data suggest that distinct mutations in Prpf31 can lead to photoreceptor degeneration through different mechanisms, by haploinsufficiency or dominant-negative effects. Analyzing the AD5 effects in our animal model in vivo, our data imply that aberrant splicing of distinct retinal transcripts contributes to the observed retina defects. KW - Factor gene PRPF31 KW - TRI-SNRNP KW - Transgenic zebrafish KW - Homebox gene KW - Chinese family KW - Mutations KW - RP11 KW - Expression KW - Disease KW - Protein KW - Retinitis pigmentosa (RP) KW - PRPF31 KW - AD5 mutation KW - SP117 mutation KW - haploinsufficiency KW - dominant-negative KW - rod degeneration KW - apoptosis KW - splicing defect Y1 - 2011 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-141090 VL - 6 IS - 56 ER - TY - THES A1 - Zellner, Elisabeth T1 - Wechselwirkungen zwischen Replikationsproteinen und Origin-DNA während Proliferation und terminaler Differenzierung T1 - Interactions between replication proteins and origin DNA during proliferation and terminal differentiation N2 - Ein Teil dieser Arbeit befasste sich mit der Fragestellung, ob beim Übergang von Proliferation zu Teilungsruhe und Differenzierung irreversible Veränderungen in der Zusammensetzung des präreplikativen Komplexes auftreten. Ein dafür geeignetes System ist die murine C2C12-Zell-Linie, die durch Kultivierung in Hungermedium zu Myotuben differenziert werden können. FACS-Analyse und BrdU-Einbau ergaben, dass in den Muskelzellen keine signifikante DNA-Synthese mehr stattfindet. Die Fluktuation von Replikationsproteinen wurde im Verlauf der terminalen Differenzierung untersucht. Gleiche Mengen an Kern- und Cytoplasma-Extrakten von proliferierenden, konfluenten und sich differenzierenden Zellen wurden durch SDS-PAGE aufgetrennt und im Immunblot mit Antikörpern gegen Replikationsproteine untersucht ORC1, CDC6, MCM6 und Geminin konnten nach 132 h nicht mehr detektiert werden, während ORC2, ORC3, MCM3, CDT1 und CDC45 zwar noch vorhanden waren, jedoch in geringerer Menge als in proliferierenden Zellen. Weiterhin wurde die Menge an Replikationsproteinen in durch Serummangel transient aus dem Zellzyklus ausgetretenen G0-Phase-Zellen und Zellen, die durch Serum reaktiviert wurden, untersucht. Die Replikationsproteine waren in quieszenten C2C12- und 3T3-Zellen gleichermaßen wie in den terminal differenzierten Zellen in verringerter Menge vorhanden. Weiterhin konnte gezeigt werden, dass eine Restimulierung von quieszenten, nicht aber terminal differenzierten Zellen, die erneute Expression von Replikationsproteinen zur Folge hat. Im Rahmen dieser Arbeit wurden Chromatin-Immunpräzipitations-Experimente (ChIP) mit proliferierenden und terminal differenzierten C2C12-Zellen durchgeführt. Eine preRC-Assemblierungsstelle befindet sich im OBR-Bereich der murinen rRNA-Gene von -2519 bis -2152 (Fragment B). In proliferierenden C2C12-Zellen konnte die Bindung von ORC1-5, CDC6, CDT1, MCM3, MCM6, CDC45 und HP1 an Fragment B nachgewiesen werden. Während der terminalen Differenzierung werden ORC1, CDC6, CDT1 und CDC45 von der preRC-Bindungsstelle entfernt, ORC2-5, MCM3, MCM6 und HP1 bleiben an Fragment B gebunden. Die Bindung von preRC-Proteinen an Fragment B sollte durch Electrophoretic Mobility Shift Assays (EMSAs) in vitro detailliert untersucht werden. Dazu mussten zunächst preRC-Proteine nativ aus dem Kernextrakt proliferierender FM3A-Zellen durch Ionenaustausch- und Gelfiltrations-Chromatographie angereichert werden. Proteine in den Fraktionen B4 bis B12 bilden einen DNA-Protein-Komplex mit Fragment B. Die ATP-Abhängigkeit der Bildung des DNA-Protein-Komplexes wurde nachgewiesen. Die Ausbildung des DNA-Protein-Komplexes erfolgt sequenzspezifisch an Fragment B. Durch Zugabe spezifischer Antikörper gegen ORC3 und CDT1 zur Bindungsreaktion konnte die Ausbildung des DNA-Protein-Komplexes reduziert werden. Es konnte gezeigt werden, dass die Bildung des DNA-Protein-Komplexes unabhängig von ATP-Hydrolyse erfolgt und dass Diadenosin-Tetraphosphat (Ap4A) die Bindung von preRC-Proteinen an die DNA nicht signifikant stimuliert. Zur Eingrenzung der preRC-Bindungsstelle wurden sowohl am 5´- als auch am 3´-Ende partiell deletierte B-Fragmente eingesetzt. Mit den um 100 bp verkürzten Fragmenten kann der DNA-Protein-Komplex weiterhin gebildet werden. Deletionen von 200 bp entweder vom 5´- oder 3´-Ende verhindern hingegen die Ausbildung des DNA-Protein-Komplexes. Auf einem 119 bp langen Fragment (-2365 bis -2247), das zentral in Fragment B gelegen ist, kann sich der DNA-Protein-Komplex in einer ATP-stimulierten Weise wiederum ausbilden. Die Analyse dieses Bereiches zeigte, dass sich darin zwei auffällige 9 bp-Sequenzen (CTCGGGAGA) befinden, die im Abstand von 63 bp wiederholt werden (-2343 bis -2335; -2280 bis -2272) und die durch die 200 bp-Deletionen ganz oder teilweise eliminiert wurden. Durch ortsgerichtete Mutagenese mittels PCR wurden innerhalb dieser 9 bp-Wiederholungen die Basen C zu A, T zu G und umgekehrt ausgetauscht. In vier sukzessiven Klonierungen wurden je 4 bp ersetzt (S1 bis S4), wobei die erhaltenen Konstrukte als Ausgangs-DNA für die nachfolgende Klonierung dienten. Die Substitutionen S1, S2 und S3 beeinträchtigten die Ausbildung des DNA-Protein-Komplexes im Wesentlichen nicht. Wurden jedoch 8 bp in beiden 9 bp-Wiederholungen ersetzt (S4), war die Ausbildung des DNA-Protein-Komplexes nahezu vollständig inhibiert. S4 hat außerdem eine leichte reduzierte elektrophoretische Mobilität der proteinfreien DNA-Fragmente zur Folge. Vermutlich stellen die 9 bp-Sequenzen jedoch keine Konsensus-Sequenz für die Bindung der preRC-Proteine per se dar, sondern haben vielmehr Effekte auf die Ausbildung spezifischer Sekundär-Strukturen, die wiederum das Binden der preRC-Proteine an diese Region im OBR der murinen rRNA-Gene erlauben könnten. N2 - One task of this work was to analyse the composition of preRCs in proliferating and terminally differentiated cells with the aim to monitor irreversible changes in the nature of preRCs upon transition from proliferation to differentiation. Murine C2C12 cells were used which can be triggered to become terminally differentiated myotubes by exposure to low mitogen medium. Differentiation was assessed by morphological examination. FACS analyses and BrdU incorporation showed the cessation of dna replication. Fluctuation of replication proteins during terminal differentiation was examined. Same amounts of nuclear and cytoplasmatic extracts, respectively, prepared from proliferating, confluent or differentiating C2C12 cells were resolved by SDS-PAGE. Immunoblot analyses were carried out using specific antibodies. After 132 h in DM ORC1, CDC6, MCM6 and geminin could not be detected in terminally differentiated myotubes at all, whereas ORC2, ORC3, MCM3, CDT1 and CDC45 were detectable, albeit at lower levels than in proliferating myoblasts. Levels of replication proteins in serum starved G0 phase cells and cells which were induced to reenter the cell cycle upon serum readdition, were investigated. Levels of replication proteins decreased in quiescent C2C12 and 3T3 cells, although different proteins were reduced to various extends. Reactivation of quiescent cells, but not terminally differentiated myotubes, resulted in reexpression of replication proteins. Chromatin immunoprecipitation analyses (ChIP) were performed comparing chromatin of proliferating cells to that of differentiated cells. A preRC binding site is localized within the OBR of the murine rRNA genes from position -2519 to -2152 (fragment B) upstream of the transcription start site. The in vivo binding of ORC1-5, CDC6, CDT1, MCM3, MCM6, CDC45 and HP1 to fragment B was observed in proliferating C2C12 cells. During terminal differentiation of C2C12 cells ORC1, CDC6, CDT1 and CDC45 are released. ORC2-5, MCM3, MCM6 and HP1, however, remain bound to fragment B. The removal of essential regulatory replication proteins like ORC1, CDC6, CDT1 and CDC45 from chromatin in terminally differentiated cells might contribute to the establishment and maintenance of an “out-of-cycle” state. One aim of the present work was to further characterize the binding of preRC proteins to fragment B in vitro by electrophoretic mobility shift assays (EMSAs). For that purpose, preRC proteins were enriched from nuclear extracts of proliferating FM3A cells by a combination of ion-exchange and gelfiltration chromatography. Purified proteins of fractions B4 to B12 caused a DNA/protein complex with fragment B. Purified preRC proteins bind exclusively to fragment B. When ORC3 and CDT1 antibodies were added to the DNA/protein binding reaction, formation of the DNA/protein complex was reduced, indicating that these proteins may play a role in formation of this DNA/protein complex. It was shown that this DNA/protein complex is formed independently of ATP hydrolysis and that diadenosine tetraphosphate (Ap4A) does not significantly stimulate binding of preRC proteins to DNA. In order to further narrow down the preRC binding site, EMSAs were performed using fragments shortened by 100 bp and 200 bp, respectively, at the 3´- or 5´-end. The DNA/protein complex is formed with both fragments truncated 100 bp at each end. However, if 200 bp are deleted, no shifts were observed, neither with fragment 5.200 nor with 3.200. On a central 119 bp fragment (-2365 to -2247) the DNA/protein complex is formed in an ATP-stimulated manner. Two conspicuous 9 bp sequence elements, CTCGGGAGA, were observed which are repeated at intervals of 63 bp (-2343 to -2335; -2280 to -2272). The sequence of these elements was altered by introducing C to A, T to G and vice versa substitutions. 4 successive substitutions of 4 bp each were constructed and the constructs were used as template DNA for subsequent mutageneses. Substitutions S1, S2 or S3 did not affect formation of the DNA/protein complex. If, however, 8 bp out of 9 bp in both sequence elements were substituted (S4), formation of the DNA/protein complex is abrogated. A naked S4 DNA fragment migrates distinctly slower than WT and S1-S3 suggesting that the secondary structure of the DNA is altered as a result of nucleotide substitutions. Probably, the 9 bp repeats do not constitute a consensus binding site per se, but rather have effects on formation of specific secondary DNA structures which in turn allow binding of preRC proteins to this region of murine rDNA. KW - Replikation KW - Proteine KW - Replikationsursprung KW - Proliferation KW - Zelldifferenzierung KW - DNA-Replikation KW - Proliferation KW - terminale Differenzierung KW - präreplikativer Komplex KW - Origin KW - DNA replication KW - proliferation KW - terminal differentiation KW - prereplicative complex KW - origin Y1 - 2005 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-15263 ER -